The key to living longer could be linked to a amazing substance, suggests the study

A new study suggests that the psilocybin, also known as magic mushrooms, could extend the life.

Researchers from the Department of Medicine of the Emory University of Atlanta, Georgia, discovered that the psilocibine extended cell life and improved survival in aging mice.

Psilocibine is the “psychedelic compound that occurs naturally produced by hallucinogenic mushrooms”, as defined in the study.

Researchers find

The researchers recently pointed out to “considerable clinical evidence” for their potential in the treatment of various psychiatric and neurodegenerative conditions.

The study, published in Nature, discovered the first experimental evidence that psilocin treatment, the “active metabolit” of the psilocibine, increases longevity in aging mice.

This suggests that the psilocybin can be a “powerful Gero -Protector Agent,” the researchers wrote.

Co -author Louise Hecker of Emory University said that the data suggests that the psilocibine affects “multiple distinctive ones of aging”.

This includes reducing levels of oxidative stress and preventing DNA damage, also known as the preservation of the “telomer length”. (Telomeres are DNA protein structures at the ends of chromosomes, which help prevent cell damage.)

Parkinson’s patients taking “magic mushrooms” see key advantages, findings of the study

“Psilocybin seems to delay the” wear “that accompanies aging,” Hecker said in an interview with Fox News Digital. “Mice and cells are healthier and live significantly longer.”

The treatment led to “a dramatic impact on the extensions of cell life” and increased the survival of mice, even when administered later in life, the researcher said.

The mice also seemed healthier, growing black hair that was previously white.

“Most of what we know about the psilocibine are the clinical results and what it does in the brain,” said Hecker. “These studies give light to the fact that psilocibine has powerful impacts throughout the body.”

More research required

As they are the first studies to show the impact of the psilocybin on aging, Hecker said that there is still “much more to learn” about the potential of the drug.

“What are optimal dosing protocols for humans? What is the optimum age for the initiation of treatment for optimal benefits?” Hecker questioned.

“The psilocibine seems to delay the” wear “that accompanies aging.”

“Is there an age, beyond what point, when the treatment does not provide effectiveness? There are possible damage or adverse effects associated with long -term treatment? What are the mechanisms of their action? All these questions must be strictly tested.”

Hecker pointed out additional studies to answer these questions and confirm if the treatment affects the life of life.

Click here to get the Fox News app

Gabe Chambides, founder of Odyssey, the first legal retirement of Psilocybin, located in Oregon, said that he believes that these findings are “convincing”.

“Although most human psilocybin trials have focused on mental health results (depression, anxiety, PTSD), this work highlights physiological changes, including cell aging markers,” he said in an interview with Fox News Digital.

Although the removal of Champitates does not test biological changes, he said that many guests report relief of physical illness such as chronic pain and migraines.

“These self -reports suggest that the effects of the mind and body that the study indicates that it also translates into humans,” he told Fox News Digital.

Click here to register -you are in our health newsletter

The administration of psilocybin should differ “abruptly” from mice to humans in terms of screening, preparation and safeguards, Chambides said.

Individuals who benefit the most from psilocybin therapy include those who “feel stuck” after significant events in life, such as child trauma, divorce, career disorder, or people, or people who seek to improve their mental health, added.

Potential risks

Ryan Moss, head of Filament Health Sciences, a natural psychedelic medicine development company in the clinical phase in Canada, emphasized the importance of administering psychedelic in a safe environment.

For more health items, visit www.foxnews.com/health

“Psychedelic experiences can sometimes have anxiety, hallucinations and paranoia,” Moss in Fox News Digital told. “Some patients who use traditional psychedelic have reported by experiencing adverse cardiovascular events during clinical trials.”

To mitigate these risks, Moss recommended that clinical trial participants be prepared and exhaustive by professionals trained during the sessions.